# IBI343

Source: https://onco.cc/drugs/ibi343/  
OnCo record `ibi343` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IBI343 is an experimental investigational agent whose form is not stated in the registry from Innovent Biologics (Suzhou) in phase 3 trials for pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.

## Summary

IBI343 is an investigational agent whose form is not stated in the registry developed by Innovent Biologics (Suzhou). Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). ClinicalTrials.gov describes the intervention as: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07066098 (A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)), in pancreatic ductal adenocarcinoma. The largest, NCT07066098, plans to enrol 201 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
- Mechanism: Investigational agent whose form is not stated in the registry directed at Claudin 18.2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Notes

- 23 Sept 2026: the payload is not stated on any record OnCo reads (registry record, sponsor page as recorded here), so the open drug engine shows IBI343 under Claudin 18.2 with the payload class not recorded rather than guessing. IBI343 (Innovent), AZD4360 (AstraZeneca) and XNW27011 are three separate records.

## Sources

- ClinicalTrials.gov: trials of IBI343: https://clinicaltrials.gov/search?intr=IBI343

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- trials: [A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)](https://onco.cc/trials/g-hope-002/), [IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct07415525/), [IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer](https://onco.cc/trials/nct06770439/), [IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer](https://onco.cc/trials/nct07692750/), [IBI343 in Combination Therapy for Advanced Malignant Solid Tumors](https://onco.cc/trials/nct07483554/)

---
JSON: https://onco.cc/api/v1/entities/ibi343.json